Autopsy report · NCT02688309

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

“Enrollment was affected due to the COVID-19 pandemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months after it had already started.
• Ran for about 6 years 9 months before it stopped.
• 44 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Johns Hopkins University

Sponsor type

University, hospital or other

Conditions

Macular Edema; Fibrosis of the Retina

Interventions

Ozurdex; Surgery; Anterior Chamber (AC) Tap

Participants

44

Sites

1

Countries

United States

Trials that died the same way

• Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
  “Enrollment slower than anticipated and interrupted by COVID-19 pandemic” (84% match in meaning)
• Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
  “Enrollment halted prematurely due to the Covid-19 pandemic” (83% match in meaning)
• Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
  “Due to enrollment difficulties compounded by the COVID pandemic.” (81% match in meaning)
• Study of the Loss of AV Synchrony at Maximum Exercise
  “No Enrollments after COVID” (79% match in meaning)
• An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
  “Recruitment/enrollment ended early due to the COVID-19 pandemic” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.